The big shareholder groups in Geron Corporation (NASDAQ:GERN) have power over the company. Large companies usually…

Evidence suggests a key decision will go its way soon.

The cancer drug company is showing no signs of slowing down after its breakout last Friday.

A key decision on its only drug in development is on tap.

With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.

The red-hot stock is reversing course.

An improved outlook for the company's lead candidate is just what investors wanted to hear.